Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Anti-Ro52 autoantibodies can be detected in patients with several autoimmune diseases. Clinical significance of anti-Ro52 is controversial. The presence of anti-Ro52 may be a factor associated with disease severity (interstitial lung disease, vasculopathy) and cancers. The aim of this study is to assess interstitial lung disease and vasculopathy prevalence and severity, cancers occurence and others clinical features of connective tissue disease patients with anti-Ro52 autoantibodies.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CTD patients with anti-Ro52 antibodies | Connective tissue disease patients with anti-Ro52 antibodies at diagnosis |
| |
| CTD patients without anti-Ro52 antibodies | Connective tissue disease patients without anti-Ro52 antibodies at diagnosis |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Follow-up | Other | Clinical data, radiological data and laboratory tests follow-up |
|
| Measure | Description | Time Frame |
|---|---|---|
| ILD prevalence | Clinical (cough, dyspnea) and/or radiological (tomodensitometry) data | baseline (J0) |
| Measure | Description | Time Frame |
|---|---|---|
| ILD severity | PFT (pulmonary function test): FVC, FEV1, DLCO (percentages of predicted values) | baseline (J0) |
| Vasculopathy occurence | Raynaud disease, digital ulcers or gangrene |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients with connective tissue disease (differenciated or not) and anti-Ro52 antibodies (as single specificity or associated with other autoantibody specificities) at diagnosis
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Roland JAUSSAUD, Pr | Contact | 0383154067 | R.JAUSSAUD@chru-nancy.fr | |
| Paul DECKER, MR | Contact | decker.paul57130@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Roland JAUSSAUD, Pr | Central Hospital, Nancy, France | Principal Investigator |
| Paul DECKER, MR | Central Hospital, Nancy, France | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Central Hospital | Completed | Dijon | France | |||
| Central Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 21447407 | Background | Ghillani P, Andre C, Toly C, Rouquette AM, Bengoufa D, Nicaise P, Goulvestre C, Gleizes A, Dragon-Durey MA, Alyanakian MA, Chretien P, Chollet-Martin S, Musset L, Weill B, Johanet C. Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study. Autoimmun Rev. 2011 Jul;10(9):509-13. doi: 10.1016/j.autrev.2011.03.004. Epub 2011 Apr 5. | |
| 28417151 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003240 | Connective Tissue Diseases |
| ID | Term |
|---|---|
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| baseline (J0) and follow-up |
| Cancer occurence | baseline (J0) and follow-up |
| Completed |
| Lille |
| France |
| Private Hospital | Recruiting | Metz | France |
|
| Central Hospital | Completed | Nancy | France |
| Background |
| Lee AYS. A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity. Rheumatol Int. 2017 Aug;37(8):1323-1333. doi: 10.1007/s00296-017-3718-1. Epub 2017 Apr 17. |
| 22394602 | Background | Hudson M, Pope J, Mahler M, Tatibouet S, Steele R, Baron M; Canadian Scleroderma Research Group (CSRG); Fritzler MJ. Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther. 2012 Mar 6;14(2):R50. doi: 10.1186/ar3763. |
| 26320136 | Background | Gunnarsson R, El-Hage F, Aalokken TM, Reiseter S, Lund MB, Garen T; Norwegian MCTD study group; Molberg O. Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease. Rheumatology (Oxford). 2016 Jan;55(1):103-8. doi: 10.1093/rheumatology/kev300. Epub 2015 Aug 28. |
| 28663326 | Background | Murng SHK, Thomas M. Clinical associations of the positive anti Ro52 without Ro60 autoantibodies: undifferentiated connective tissue diseases. J Clin Pathol. 2018 Jan;71(1):12-19. doi: 10.1136/jclinpath-2015-203587. Epub 2017 Jun 29. |
| 28379478 | Background | Reiseter S, Gunnarsson R, Mogens Aalokken T, Lund MB, Mynarek G, Corander J, Haydon J, Molberg O. Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study. Rheumatology (Oxford). 2018 Feb 1;57(2):255-262. doi: 10.1093/rheumatology/kex077. |
| 27252419 | Background | Bauhammer J, Blank N, Max R, Lorenz HM, Wagner U, Krause D, Fiehn C. Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response. J Rheumatol. 2016 Aug;43(8):1566-74. doi: 10.3899/jrheum.150844. Epub 2016 Jun 1. |